NY-MOODYS/THOMSON-REUTER
Moody’s Analytics, a leading provider of financial intelligence and analytics, partners with Thomson Reuters Financial and Risk business to offer a classification solution for conducting the Solely for Payment of Principal and Interest (SPPI) tests required under the IFRS9 accounting standard. The solution allows fixed-income investors to automate SPPI tests for securities in their portfolios by providing data on over 1.2 million corporate, government, and structured securities globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005527/en/
“We are pleased to partner with Thomson Reuters to bring fixed-income investors more comprehensive coverage of all asset classes in a single transparent and auditable solution,” said Luis Amador, Managing Director at Moody’s Analytics.
In addition to securities held in clients’ portfolios, the solution permits users to conduct additional due diligence on bonds that have not been purchased. Full explanations are provided for returned SPPI pass/fail tests, including the methodologies used, as well as IFRS9 identified criteria and interpretations.
“Partnering with Moody’s Analytics, we developed a much simpler and more comprehensive solution to help clients manage their SPPI instrument accounting obligations under IFRS9,” said Stuart Martin, Managing Director for Risk Information and Learning Services for the Financial & Risk business at Thomson Reuters. “We worked together to deliver a seamless experience for clients, built on industry-leading data from both Thomson Reuters and Moody’s Analytics.”
The SPPI data feed is delivered with an open API and can be integrated into an existing client system or accessed via a web portal. “We developed the solution with user experience in mind and are committed to providing expert customer service throughout the product lifecycle,” added Mr. Amador.
Click here to learn more about the Moody’s Analytics/Thomson Reuters SPPI classification solution for IFRS9.
About Moody’s Analytics
Moody’s Analytics provides financial
intelligence and analytical tools to help business leaders make better,
faster decisions. Our deep risk expertise, expansive information
resources, and innovative application of technology help our clients
confidently navigate an evolving marketplace. We are known for our
industry-leading and award-winning solutions, made up of research, data,
software, and professional services, assembled to deliver a seamless
customer experience. We create confidence in thousands of organizations
worldwide, with our commitment to excellence, open mindset approach, and
focus on meeting customer needs. For more information about Moody’s
Analytics, visit www.moodysanalytics.com
.
Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). MCO reported revenue of $4.2 billion in 2017, employs approximately 12,300 people worldwide and maintains a presence in 42 countries.
About Thomson Reuters
Thomson Reuters is the world’s leading
source of news and information for professional markets. Our customers
rely on us to deliver the intelligence, technology and expertise they
need to find trusted answers. The business has operated in more than 100
countries for more than 100 years. Thomson Reuters shares are listed on
the Toronto and New York Stock Exchanges. For more information, visit www.thomsonreuters.com
.
The Thomson Reuters Financial & Risk business will be known as Refinitiv , following the closing of the strategic partnership transaction between Thomson Reuters and private equity funds managed by Blackstone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180926005527/en/
Contact:
Moody’s Analytics Communications KATERINA SOUMILOVA, +1-212-553-1177 Assistant Vice-President katerina.soumilova@moodys.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom